vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and PAMT CORP (PAMT). Click either name above to swap in a different company.
PAMT CORP is the larger business by last-quarter revenue ($141.3M vs $83.5M, roughly 1.7× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -20.7%, a 27.5% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -15.1%). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $-25.0M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
BLLN vs PAMT — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $141.3M |
| Net Profit | $5.7M | $-29.3M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | -27.0% |
| Net Margin | 6.8% | -20.7% |
| Revenue YoY | 117.4% | -15.1% |
| Net Profit YoY | 138.3% | 7.4% |
| EPS (diluted) | $0.10 | $-1.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $141.3M | ||
| Q3 25 | $83.5M | $150.3M | ||
| Q2 25 | — | $151.1M | ||
| Q1 25 | — | $155.3M | ||
| Q4 24 | — | $166.5M | ||
| Q3 24 | $38.4M | $182.6M | ||
| Q2 24 | — | $182.9M | ||
| Q1 24 | — | $182.6M |
| Q4 25 | — | $-29.3M | ||
| Q3 25 | $5.7M | $-5.6M | ||
| Q2 25 | — | $-9.6M | ||
| Q1 25 | — | $-8.1M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | $-14.9M | $2.4M | ||
| Q2 24 | — | $-2.9M | ||
| Q1 24 | — | $281.0K |
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -27.0% | ||
| Q3 25 | 11.5% | -3.8% | ||
| Q2 25 | — | -7.3% | ||
| Q1 25 | — | -5.9% | ||
| Q4 24 | — | -22.6% | ||
| Q3 24 | -32.9% | 1.3% | ||
| Q2 24 | — | -0.4% | ||
| Q1 24 | — | -0.4% |
| Q4 25 | — | -20.7% | ||
| Q3 25 | 6.8% | -3.7% | ||
| Q2 25 | — | -6.4% | ||
| Q1 25 | — | -5.2% | ||
| Q4 24 | — | -19.0% | ||
| Q3 24 | -38.8% | 1.3% | ||
| Q2 24 | — | -1.6% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | $-1.38 | ||
| Q3 25 | $0.10 | $-0.27 | ||
| Q2 25 | — | $-0.46 | ||
| Q1 25 | — | $-0.37 | ||
| Q4 24 | — | $-1.44 | ||
| Q3 24 | $-1.47 | $0.11 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $83.7M |
| Total DebtLower is stronger | $55.0M | $333.9M |
| Stockholders' EquityBook value | $-239.5M | $210.5M |
| Total Assets | $327.5M | $697.9M |
| Debt / EquityLower = less leverage | — | 1.59× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $83.7M | ||
| Q3 25 | $195.2M | $115.6M | ||
| Q2 25 | — | $117.3M | ||
| Q1 25 | — | $102.7M | ||
| Q4 24 | — | $110.7M | ||
| Q3 24 | — | $92.3M | ||
| Q2 24 | — | $114.0M | ||
| Q1 24 | — | $125.8M |
| Q4 25 | — | $333.9M | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $325.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $210.5M | ||
| Q3 25 | $-239.5M | $239.5M | ||
| Q2 25 | — | $244.9M | ||
| Q1 25 | — | $269.6M | ||
| Q4 24 | — | $277.5M | ||
| Q3 24 | $-242.9M | $308.9M | ||
| Q2 24 | — | $306.7M | ||
| Q1 24 | — | $314.6M |
| Q4 25 | — | $697.9M | ||
| Q3 25 | $327.5M | $715.2M | ||
| Q2 25 | — | $707.9M | ||
| Q1 25 | — | $712.6M | ||
| Q4 24 | — | $741.7M | ||
| Q3 24 | — | $756.7M | ||
| Q2 24 | — | $733.5M | ||
| Q1 24 | — | $746.4M |
| Q4 25 | — | 1.59× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $-5.8M |
| Free Cash FlowOCF − Capex | $6.5M | $-25.0M |
| FCF MarginFCF / Revenue | 7.7% | -17.7% |
| Capex IntensityCapex / Revenue | 8.8% | 13.6% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-23.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-5.8M | ||
| Q3 25 | $13.8M | $5.9M | ||
| Q2 25 | — | $12.2M | ||
| Q1 25 | — | $5.0M | ||
| Q4 24 | — | $15.2M | ||
| Q3 24 | — | $15.5M | ||
| Q2 24 | — | $18.7M | ||
| Q1 24 | — | $9.6M |
| Q4 25 | — | $-25.0M | ||
| Q3 25 | $6.5M | $2.5M | ||
| Q2 25 | — | $5.9M | ||
| Q1 25 | — | $-6.8M | ||
| Q4 24 | — | $-39.9M | ||
| Q3 24 | — | $-33.6M | ||
| Q2 24 | — | $4.1M | ||
| Q1 24 | — | $-12.2M |
| Q4 25 | — | -17.7% | ||
| Q3 25 | 7.7% | 1.7% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | -4.4% | ||
| Q4 24 | — | -24.0% | ||
| Q3 24 | — | -18.4% | ||
| Q2 24 | — | 2.2% | ||
| Q1 24 | — | -6.7% |
| Q4 25 | — | 13.6% | ||
| Q3 25 | 8.8% | 2.3% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 7.6% | ||
| Q4 24 | — | 33.1% | ||
| Q3 24 | — | 26.9% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | — | 12.0% |
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.44× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 34.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
